Fulcrum Therapeutics, Inc. (NasdaqGM: FULC)
Health Care · Pharmaceuticals · US
$3.75
-0.66% today · -60.8% 1Y
Fulcrum Therapeutics, Inc. (NasdaqGM: FULC) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $287.64M and employs 9 people.
Over the last twelve months the share price has lost 60.8%, trading between 2.83 and 15.74.
Tweenvest scores Fulcrum Therapeutics, Inc. across four factors: quality 38/100, value 41/100. Its strongest factor is value.
FULC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $287.64M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.21
- Dividend yield
- —
- Beta (5Y)
- 2.63
- 52-week high
- $15.74
- 52-week low
- $2.83
- Avg volume (3M)
- —
- Shares outstanding
- 76.30M
- Employees
- 9
- Next earnings
- —
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
- ISIN
- US3596161097
- Founded
- 2015
- Listed since
- Jul 18, 2019
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Fuji Pharma Co., Ltd.TSE: 4554 | $293.63M | ¥1,780.00 | +3.49% |
| EyePoint, Inc.NasdaqGM: EYPT | $293.12M | $3.30 | -3.09% |
| BioAge Labs, Inc.NasdaqGS: BIOA | $290.99M | $5.94 | -6.31% |
| Lavipharm S.A.ATSE: LAVI | $288.74M | €1.51 | -3.70% |
| Hua Medicine (Shanghai) Ltd.SEHK: 2552 | $283.77M | HK$2.23 | -4.90% |
| Tiansheng Pharmaceutical Group Co., Ltd.SZSE: 002872 | $283.43M | CN¥5.97 | -3.55% |
| Starpharma Holdings LimitedASX: SPL | $282.89M | AU$0.85 | +5.62% |
| Antibiotice S.A.BVB: ATB | $281.52M | RON2.00 | +0.20% |
Figures last refreshed Oct 11, 2026.